Peg-intron and Vistaril drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Peg-intron (peginterferon alfa-2b) and Vistaril (hydroxyzine hydrochloride). Common drug interactions include anaemia among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Peg-intron and Vistaril. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Peg-intron?

Peg-intron has active ingredients of peginterferon alfa-2b. eHealthMe is studying from 11,142 Peg-intron users. Check the latest studies of Peg-intron.

What is Vistaril?

Vistaril has active ingredients of hydroxyzine hydrochloride. It is often used in stress and anxiety. eHealthMe is studying from 9,565 Vistaril users. Check the latest studies of Vistaril.



On Jul, 08, 2026

11 people who take Peg-intron and Vistaril together, and have interactions are studied.

Peg-intron and Vistaril drug interactions.

What are the common drug interactions of Peg-Intron and Vistaril, by gender? *:

female:

  1. Anaemia (lack of blood)
  2. Anger
  3. Ankle fracture
  4. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  5. Dehydration (dryness resulting from the removal of water)
  6. Depression
  7. Disease progression
  8. Impulsive behaviour
  9. Joint sprain (an injury to joint surrounding flexible fibres)
  10. Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking)

male:

  1. Fatigue (feeling of tiredness)
  2. Nausea (feeling of having an urge to vomit)
  3. Dehydration (dryness resulting from the removal of water)
  4. Depression
  5. Dizziness
  6. Dry skin
  7. Empyema (collection of pus in a cavity in the body)
  8. Haemoglobin decreased
  9. Pneumonia
  10. Rash

What are the common drug interactions of Peg-Intron and Vistaril, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Anaemia (lack of blood)
  2. Anger
  3. Ankle fracture
  4. Dehydration (dryness resulting from the removal of water)
  5. Depression
  6. Disease progression
  7. Impulsive behaviour
  8. Joint sprain (an injury to joint surrounding flexible fibres)
  9. Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking)
  10. Pain

40-49:

  1. Confusional state
  2. Dyspnoea (difficult or laboured respiration)
  3. Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
  4. Muscle spasms (muscle contraction)
  5. Suicidal ideation
  6. Tooth abscess (pus formation in tooth)
  7. Empyema (collection of pus in a cavity in the body)
  8. Pneumonia
  9. Anger
  10. Blood thyroid stimulating hormone increased

50-59:

  1. Fatigue (feeling of tiredness)
  2. Haemoglobin decreased
  3. Nausea (feeling of having an urge to vomit)
  4. Rash
  5. Weight decreased
  6. Application site pruritus (application site severe itching of the skin)
  7. Blood triglycerides increased
  8. Pruritus (severe itching of the skin)
  9. Skin lesion
  10. Blood glucose increased

60+:

  1. Cellulitis (infection under the skin)
  2. Diarrhoea
  3. Full blood count decreased
  4. Thrombosis (formation of a blood clot inside a blood vessel)

What are the existing conditions these people have? *

  1. Hepatitis C: 11 people, 100.00%
  2. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 1 person, 9.09%
  3. Depression: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Peg-intron and Vistaril?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Peg-intron and Vistaril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Peg-intron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Vistaril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Peg-intron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vistaril and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on peginterferon alfa-2b and hydroxyzine hydrochloride (the active ingredients of Peg-intron and Vistaril, respectively), and Peg-intron and Vistaril (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: